Biotech Information sources Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Information sources

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (72)	10/6/2003 9:03:39 PM
From: scaram(o)uche	Read Replies (2) of 269

In Vivo..... it's been around for a long time. Every report that I read (maybe 5-6 years ago??) showed insight. Good stuff. However, that MAb blurb was kinda funky, and this is just plain comedy material...... And importantly, besides Humira (which of course was developed by BASF, not one of the antibody platform-turned-product biotechs), there’s little evidence of having the ability to optimize the antibody against a target. That may be because while antibodies are a central tool in pharma genomics programs, they’ve been used as a research tool to validate the target, not the antibody itself as a drug. For example, Pfizer has been working with Abgenix’s technology for six years. But it has yet to get an antibody molecule through proof-of-concept testing, when presumably such trials would be publicly known. One reason could be that it was using antibodies as a target validation tool So, Knoll can be clearly differentiated from a biotech? And CATG isn't a "platform-turned-product" biotech? And the Abgenix/Pfizer comment is hilarious, so far off the mark that one better hope that the author didn't also write the abstracted blurb.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next